Capital Research Global Investors Raises Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Key Points

• Capital Research Global Investors raised its stake in IDEXX to 690,601 shares (an increase of 5,641 shares), owning about 0.86% of the company worth roughly $441.2M.
• Wall Street consensus is a Moderate Buy with a $783.33 average target, though several analysts recently trimmed price targets and ratings.
• IDEXX reported Q results with EPS of $2.92 (missed by $0.01) and revenue of $1.09B (+14.3% YoY) and set FY‑2026 EPS guidance of 14.29–14.80; insiders have sold ~45,957 shares (~$29.9M) in the last 90 days while institutions own 87.84% of the stock.

Capital Research Global Investors increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 0.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 690,601 shares of the company's stock after purchasing an additional 5,641 shares during the period. Capital Research Global Investors owned approximately 0.86% of IDEXX Laboratories worth $441,218,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bank of Montreal Can increased its holdings in shares of IDEXX Laboratories by 14.9% in the 3rd quarter. Bank of Montreal Can now owns 139,126 shares of the company's stock worth $88,886,000 after buying an additional 18,025 shares during the last quarter. Legal & General Group Plc grew its position in IDEXX Laboratories by 4.1% in the third quarter. Legal & General Group Plc now owns 675,535 shares of the company's stock worth $431,593,000 after acquiring an additional 26,909 shares in the last quarter. Vestcor Inc increased its stake in IDEXX Laboratories by 77.8% in the third quarter. Vestcor Inc now owns 3,772 shares of the company's stock valued at $2,410,000 after acquiring an additional 1,651 shares during the last quarter. WINTON GROUP Ltd bought a new position in IDEXX Laboratories in the third quarter valued at $1,335,000. Finally, LGT Group Foundation raised its position in IDEXX Laboratories by 5.7% during the third quarter. LGT Group Foundation now owns 1,231 shares of the company's stock valued at $763,000 after purchasing an additional 66 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Wall Street Zen lowered IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 28th. UBS Group reduced their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 3rd. BTIG Research reduced their target price on IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating on the stock in a report on Tuesday, February 3rd. Piper Sandler decreased their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating for the company in a research note on Monday, February 9th. Finally, Weiss Ratings lowered IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, January 29th. Seven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus target price of $783.33.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $598.85 on Wednesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The company has a market cap of $47.68 billion, a P/E ratio of 45.82, a P/E/G ratio of 3.71 and a beta of 1.66. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $769.98. The firm's fifty day moving average is $663.72 and its two-hundred day moving average is $668.13.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts' consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.09 billion during the quarter, compared to analysts' expectations of $1.07 billion. During the same period in the previous year, the business earned $2.53 earnings per share. The business's quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Activity

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president directly owned 9,823 shares of the company's stock, valued at $6,352,730.56. The trade was a 53.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Sophie V. Vandebroek sold 1,464 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the sale, the director directly owned 648 shares in the company, valued at $407,345.76. This trade represents a 69.32% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 45,957 shares of company stock valued at $29,862,109. Insiders own 0.98% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.